HER2-targeted antibody-drug conjugate (ADC)

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Enhertu Receives US Approval as First HER2-focused Treatment for Metastatic Solid Tumors, Independent of Tumor Origin AstraZeneca and Daiichi Sankyo's drug Enhertu (trastuzumab deruxtecan) has gained approval in the United States for treating adult patients with inoperable or metastatic HER2-positive (IHC 3+) so...

Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disord...